Sequence: r9-x-c
| Experiment Id | EXP001672 |
|---|---|
| Paper | Tumor-Targeting and Microenvironment-Responsive Smart Nanoparticles for Combination Therapy of Antia |
| Peptide | r9 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | medium |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Apoptosis assay under pH 6.0; concentrations as in Figure 7A (dose-response) |
| Rna Concentration | DNA (dose-response) + DOX (intercalated; w/w ~1:0.16) |
| Mixing Ratio | DGL:DNA w/w 6:1; DOX intercalated |
| Formulation Format | PEGylated DGL nanoparticles (peptide-PEG-DGL/DNA complexes) |
| Formulation Components | Dendrigraft poly-L-lysine (DGL G3) + MAL-PEG-NHS (PEG 3500) + r9 CPP; complexes with plasmid shVEGF (± DOX intercalated) |
| Size Nm | 145.00 |
| Zeta Mv | 2.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | U-87 MG (human malignant glioma) cells |
| Animal Model | |
| Administration Route | |
| Output Type | functional effect (apoptosis) |
| Output Value | Dose-dependent apoptosis observed (Figure 7A) |
| Output Units | |
| Output Notes | CPPD/shVEGF-DOX included in in vitro apoptosis comparison; not advanced to in vivo in this paper |
| Toxicity Notes | Not detailed |
| Curation Notes |